It belongs to a novel class of drugs known as triple agonists, meaning it simultaneously activates three hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor
By comparison, a 3 mg dose of liraglutide, another medication, resulted in a 9% weight loss, while the placebo group only experienced a 3% reduction
However, clinical research increasingly recognized that patients with metabolic diseases frequently experience clusters of systemic complications, including heart failure (HF), chronic kidney disease (CKD), and fatty liver disease, that single-target drugs historically failed to address comprehensively
For instance, the LillyDirect self-pay option allows you to buy Zepbound directly from the manufacturer for a reduced price (starting at $299)
There's no strong evidence that one site causes fewer systemic side effects (like nausea) than another
Bottom right, RMSF values plotted on the GLP-1R structure bound to TT-OAD2 (transparent stick representation)